Abstract: An information processing device includes a communication unit and a control unit. The control unit is configured to determine a sprinkling mode based on information indicating the environment of a sprinkling place. The control unit is configured to send, through the communication unit, a notification indicating the sprinkling mode to at least one vehicle scheduled to travel in the sprinkling place.

Abstract: [Problem] The objectives of the present invention are to provide a method for making an animal that has been stressed, in particular, chronically stressed, affect or develop a specific disease or symptom, and, through elucidating the process from loading stress to affection or onset of the disease or symptom, to provide a useful tool for research and development of preventing or treating methods of the disease or symptom. [Solution] The present invention relates to a method for producing a disease modeling non-human animal having cerebrovascular inflammation, the disease modeling non-human animal, a method for screening a drug using the disease modeling non-human animal, a method for determining the risk of a disease using the presence of cerebrovascular inflammation as an indicator, and a pharmaceutical for preventing and/or treating progressive multiple sclerosis or the like.

Abstract: The present invention provides a method for assessing the possibility of onset or progression of chronic kidney allograft rejection or chronic kidney disease in a test subject, by using, as an indicator, the level of SYT17 protein in a urine-derived specimen collected from the test subject. The present invention also provides: a pharmaceutical composition for preventing and/or treating chronic kidney allograft rejection or chronic kidney disease, the pharmaceutical composition including at least one substance selected from the group consisting of a specific antibody to SYT17, a derivative of the specific antibody, and an inhibitory nucleic acid against SYT17; and a test kit for use in assessing the possibility of onset or progression of chronic kidney allograft rejection or chronic kidney disease, the test kit including a specific antibody to SYT17 or a derivative of the specific antibody.

Abstract: The present invention pertains to a medicine, said medicine comprising as an active ingredient a substance which suppresses the expression of at least one molecule selected from the group consisting of TMEM5, VSTM2L, C2CDD4D, VSTM2A, LY6G6C and ADRA2C or inhibits the activity thereof, for preventing and/or treating at least one disease or symptom selected from the group consisting of progressive multiple sclerosis, gastroenteritis, myocardial disorder and sudden death. Also, the present invention pertains to a method for screening a substance, which is capable of preventing and/or treating at least one disease or symptom selected from the group consisting of progressive multiple sclerosis, gastroenteritis, myocardial disorder and sudden death, with the use of the expression or activity of the aforesaid molecule as an index.

Abstract: [Problem] The purpose of the present invention is to provide new treatment targets and treatment methods for chronic inflammatory disease based on a molecular biological mechanism relating to the onset of keloid. [Solution] The present invention relates to a drug for the prevention and/or treatment of chronic inflammatory disease that contains as an active ingredient a substance that suppresses the expression and/or inhibits the activity of a specific NEDD4 splicing variant protein.

Abstract: [Problem] The objectives of the present invention are to provide a method for making an animal that has been stressed, in particular, chronically stressed, affect or develop a specific disease or symptom, and, through elucidating the process from loading stress to affection or onset of the disease or symptom, to provide a useful tool for research and development of preventing or treating methods of the disease or symptom. [Solution] The present invention relates to a method for producing a disease modeling non-human animal having cerebrovascular inflammation, the disease modeling non-human animal, a method for screening a drug using the disease modeling non-human animal, a method for determining the risk of a disease using the presence of cerebrovascular inflammation as an indicator, and a pharmaceutical for preventing and/or treating progressive multiple sclerosis or the like.